vociprotafib   Click here for help

GtoPdb Ligand ID: 12067

Synonyms: compound A-290 [WO2018013597A1] | RMC-4630 | RMC4630 | SAR-442720 | SAR442720 | SHP2-IN-7
Compound class: Synthetic organic
Comment: RMC-4630 (Revolution Medicines) is a clinical stage oral, allosteric SHP2 (PTPN11) inhibitor [1] that is being evaluated for efficacy against advanced solid tumours. SHP2 is a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signalling pathway which is often hyperactivated in tumours.
We matched RMC-4630's chemical structure to the INN 'vociprotafib' which was released in the WHO's proposed INN list 127 on 21 July 2022.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 148.71
Molecular weight 450.16
XLogP 1.76
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCc1nc(Sc2ccnc(c2Cl)N)c(nc1N1CCC2(CC1)CO[C@H]([C@H]2N)C)C
Isomeric SMILES C[C@H]1[C@H](C2(CCN(CC2)c2nc(c(nc2CO)Sc2c(c(ncc2)N)Cl)C)CO1)N
InChI InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1
InChI Key HISJAYUQVHMWTA-BLLLJJGKSA-N
References
1. Jogalekar A, Won W, Koltun ES, Gill A, Mellem K, Aay N, Buckl A, Semko C, Kiss G. (2018)
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors.
Patent number: WO2018013597A1. Assignee: Revolution Medicines, Inc.. Priority date: 12/07/2016. Publication date: 18/01/2018.